Pharmacological treatment of mixed states

CNS Spectrums

Volumn 22, Issue 2, 2017, Pages 186-195

  Cuomo, Alessandro ^a   Nikolova, Viktoriya L ^b   Yalin, Nefize ^b   Arnone, Danilo ^b   Fagiolini, Andrea ^a   Young, Allan H ^b  

^a UNIVERSITY OF SIENA   (Italy)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

depressive symptoms; DSM 5; manic symptoms; Mixed states episodes; mood disorders; pharmacological interventions; pharmacotherapies; treatment

Indexed keywords

ARIPIPRAZOLE; ASENAPINE; CARBAMAZEPINE; CLOZAPINE; FLUOXETINE PLUS OLANZAPINE; LAMOTRIGINE; LITHIUM SALT; LURASIDONE; MOOD STABILIZER; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; VALPROIC ACID; ZIPRASIDONE; ANTIDEPRESSANT AGENT; NEUROLEPTIC AGENT; TRANQUILIZER;

BIPOLAR DEPRESSION; BIPOLAR DISORDER; DEPRESSION; DRUG EFFICACY; DSM-5; DSM-III; DSM-IV; HUMAN; LONG TERM CARE; MAINTENANCE THERAPY; MAJOR DEPRESSION; MANIA; MONOTHERAPY; MOOD DISORDER; RELAPSE; REMISSION; REVIEW; SYSTEMATIC REVIEW; CLASSIFICATION; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; PSYCHOLOGY; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG THERAPY, COMBINATION; HUMANS; TREATMENT OUTCOME;

EID: 85017503487     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852917000013     Document Type: Review

References (63)

1. Swann AC, Lafer B, Perugi G, et al. Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure, course of illness, and diagnosis. Am J Psychiatry. 2013; 170(1): 31-42. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2012.12030301. Accessed January 8, 2017.
2. Vieta E, Valenti M. Mixed states in DSM-5: implications for clinical care, education, and research. J Affect Disord. 2013; 148(1): 28-36. Epub ahead of print Apr 2. http://www.jad-journal.com/article/S0165-0327(13)00232-2/pdf. Accessed January 8, 2017.
3. Castle DJ. Bipolar mixed states: still mixed up?. Curr Opin Psychiatry. 2014; 27(1): 38-42.
4. Houston JP, Ahl J, Meyers AL, Kaiser CJ, Tohen M, Baldessarini RJ. Reduced suicidal ideation in bipolar I disorder mixed-episode patients in a placebo-controlled trial of olanzapine combined with lithium or divalproex. J Clin Psychiatry. 2006; 67(8): 1246-1252.
5. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-Analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009; 151(4): W65-W94. Epub ahead of print Jul 20.
6. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999; 156(5): 702-709. http://ajp.psychiatryonline.org/doi/pdf/10.1176/ajp.156.5.702. Accessed January 8, 2017.
7. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group. Arch Gen Psychiatry. 2000; 57(9): 841-849. http://jamanetwork.com/journals/jamapsychiatry/fullarticle/205739. Accessed January 8, 2017.
8. Novick D, Reed C, Haro JM, et al. Comparison of olanzapine and risperidone in the EMBLEM Study: translation of randomized controlled trial findings into clinical practice. Int Clin Psychopharmacol. 2010; 25(5): 257-263.
9. Perlis RH, Baker RW, Zarate CA Jr, et al. Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry. 2006; 67(11): 1747-1753.
10. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs. haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003; 60(12): 1218-1226. http://jamanetwork.com/journals/jamapsychiatry/fullarticle/208076. Accessed January 8, 2017.
11. Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005; 162(7): 1281-1290. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.162.7.1281. Accessed January 8, 2017.
12. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine versus olanzapine in acute mania: a double-blind extension study. Bipolar Disord. 2009; 11(8): 815-826. Epub ahead of print Oct 14.
13. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003; 160(7): 1263-1271. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.160.7.1263. Accessed January 8, 2017.
14. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry. 2004; 184: 337-345. http://bjp.rcpsych.org/content/184/4/337.long. Accessed January 8, 2017.
15. Weisler RH, Nolen WA, Neijber A, Hellqvist A, Paulsson B. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (trial 144: a randomized controlled study). J Clin Psychiatry. 2011; 72(11): 1452-1464.
16. Vieta E, Suppes T, Eggens I, Persson I, Paulsson B, Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126). J Affect Disord. 2008; 109(3): 251-263. Epub ahead of print Jun 24.
17. Suppes T, Vieta E, Liu S, Brecher M, Paulsson B. Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (trial 127). Am J Psychiatry. 2009; 166(4): 476-488. Epub ahead of print Mar 16. http://ajp.psychiatryonline.org/doi/pdfplus/10.1176/appi.ajp.2008.08020189. Accessed January 8, 2017.
18. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003; 160(9): 1651-1658. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.160.9.1651. Accessed January 8, 2017.
19. Keck PE, Orsulak PJ, Cutler AJ, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- And lithium-controlled study. J Affect Disord. 2009; 112(1-3): 36-49. Epub ahead of print Oct 2, 2008.
20. Young AH, Oren DA, Lowy A, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- And haloperidolcontrolled study. Br J Psychiatry. 2008, 194(1): 40-48. http://bjp.rcpsych.org/content/194/1/40.long. Accessed January 8, 2017.
21. Keck PE Jr, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry. 2007; 68(10): 1480-1491.
22. Findling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009; 70(10): 1441-1451.
23. Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry. 2005; 187: 235-242. http://bjp.rcpsych.org/content/187/3/235.long. Accessed January 8, 2017.
24. Vieta E, T?Joen C, McQuade RD, et al. Efficacy of adjunctive aripiprazole to either valproate or lithium in bipolar mania patients partially nonresponsive to valproate/lithium monotherapy: a placebo-controlled study. Am J Psychiatry. 2008; 165(10): 1316-1325. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.2008.07101560. Accessed January 8, 2017.
25. Marcus R, Khan A, Rollin L, et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-Term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord. 2011; 13(2): 133-144.
26. Vieta E, Owen R, Baudelet C, McQuade RD, Sanchez R, Marcus RN. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, openlabel extension following a 6-week double-blind study. CurrMed Res Opin. 2010; 26(6): 1485-1496.
27. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine for long-Term treatment of bipolar disorder: a doubleblind 40-week extension study. J Affect Disord. 2010; 126(3): 358-365.
28. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. Asenapine in the treatment of acute mania in bipolar I disorder: a randomized, double-blind, placebo-controlled trial. J Affect Disord. 2010; 122(1-2): 27-38.
29. Bowden CL, Vieta E, Ice KS, Schwartz JH, Wang PP, Versavel M. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, doubleblind trial. J Clin Psychiatry. 2010; 71(2): 130-137.
30. Keck PE Jr, Versiani M, Potkin S, West SA, Giller E, Ice K. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003; 160(4): 741-748. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.160.4.741. Accessed January 8, 2017.
31. Potkin SG, Keck PE Jr, Segal S, Ice K, English P. Ziprasidone in acute bipolar mania: a 21-day randomized, double-blind, placebocontrolled replication trial. J Clin Psychopharmacol. 2005; 25(4): 301-310.
32. Vieta E, Nuamah IF, Lim P, et al. A randomized, placebo- And activecontrolled study of paliperidone extended release for the treatment of acute manic and mixed episodes of bipolar I disorder. Bipolar Disord. 2010; 12(3): 230-243.
33. Berwaerts J, Xu H, Nuamah I, Lim P, Hough D. Evaluation of the efficacy and safety of paliperidone extended-release in the treatment of acute mania: a randomized, double-blind, dose-response study. J Affect Disord. 2012; 136(1-2): e51-e60. Epub ahead of print Jul 10, 2010.
34. Khanna S, Vieta E, Lyons B, Grossman F, Eerdekens M, Kramer M. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry. 2005; 187: 229-234. http://bjp.rcpsych.org/content/187/3/229.long. Accessed January 8, 2017.
35. Sachs GS, Greenberg WM, Starace A, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, phase III trial. J Affect Disorders. 2015; 174: 296-302. Epub ahead of print Nov 24, 2014. http://www.jadjournal. com/article/S0165-0327(14)00728-9/pdf. Accessed January 8, 2017.
36. Durgam S, Starace A, Li D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015; 17(1): 63-75. Epub ahead of print Jul 24, 2014.
37. Calabrese JR, Keck PE Jr, Starace A, et al. Efficacy and safety of lowand high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015; 76(3): 284-292.
38. Bowden CL, Swann AC, Calabrese JR, et al. A randomized, placebocontrolled, multicenter study of divalproex sodium extended release in the treatment of acute mania. J Clin Psychiatry. 2006; 67(10): 1501-1510.
39. Freeman TW, Clothier JL, Pazzaglia P, Lesem MD, Swann AC. A double-blind comparison of valproate and lithium in the treatment of acute mania. Am J Psychiatry. 1992; 149(1): 108-111.
40. Bowden CL, Calabrese JR, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Arch Gen Psychiatry. 2003; 60(4): 392-400. http://jamanetwork. com/journals/jamapsychiatry/fullarticle/207328. Accessed January 8, 2017.
41. Calabrese JR, Bowden CL, Sachs G, et al. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently depressed patients with bipolar I disorder. J Clin Psychiatry. 2003; 64(9): 1013-1024.
42. Perugi G, Toni C, Ruffolo G, Sartini S, Simonini E, Akiskal H. Clinical experience using adjunctive gabapentin in treatmentresistant bipolar mixed states. Pharmacopsychiatry. 1999; 32(4): 136-141.
43. Suppes T, Eudicone J, McQuade R, Pikalov A 3rd, Carlson B. Efficacy and safety of aripiprazole in subpopulations with acute manic or mixed episodes of bipolar I disorder. J Affect Disord. 2008; 107(1-3): 145-154. Epub ahead of print Sep 27, 2007.
44. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006; 20(4): 536-546. http://journals.sagepub.com/doi/pdf/10.1177/0269881106059693. Accessed January 8, 2017.
45. McIntyre RS, Cohen M, Zhao J, Alphs L, Macek TA, Panagides J. A 3-week, randomized, placebo-controlled trial of asenapine in the treatment of acute mania in bipolar mania and mixed states. Bipolar Disord. 2009; 11(7): 673-686.
46. Suppes T, Silva R, Cucchiaro J, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double-blind, placebo-controlled study. Am J Psychiatry. 2016; 173(4): 400-407. Epub ahead of print Nov 10, 2015.
47. Patkar A, Gilmer W, Pae CU, et al. A 6-week randomized doubleblind placebo-controlled trial of ziprasidone for the acute depressive mixed state. PloS One. 2012; 7(4): e34757. Epub ahead of print Apr 24. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3335844/. Accessed January 8, 2017.
48. Stahl S, Lombardo I, Loebel A, Mandel FS. Efficacy of ziprasidone in dysphoric mania: pooled analysis of two double-blind studies. J Affect Disord. 2010; 122(1-2): 39-45. Epub ahead of print Jul 17, 2009.
49. Suppes T, McElroy SL, Gilbert J, Dessain EC, Cole JO. Clozapine in the treatment of dysphoric mania. Biol Psychiatry. 1992; 32(3): 270-280.
50. Weisler RH, Hirschfeld R, Cutler AJ, et al. Extended-release carbamazepine capsules as monotherapy in bipolar disorder: pooled results from two randomised, double-blind, placebocontrolled trials. CNS Drugs. 2006; 20(3): 219-231.
51. Weisler RH, Kalali AH, Ketter TA. A multicenter, randomized, double-blind, placebo-controlled trial of extended-release carbamazepine capsules as monotherapy for bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry. 2004; 65(4): 478-484.
52. Weisler RH, Keck PE Jr, Swann AC, Cutler AJ, Ketter TA, Kalali AH. Extended-release carbamazepine capsules as monotherapy for acute mania in bipolar disorder: a multicenter, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2005; 66(3): 323-330.
53. Houston JP, Tohen M, Degenhardt EK, Jamal HH, Liu LL, Ketter TA. Olanzapine-divalproex combination versus divalproex monotherapy in the treatment of bipolar mixed episodes: a doubleblind, placebo-controlled study. J Clin Psychiatry. 2009; 70(11): 1540-1547. Epub ahead of print Sep 22.
54. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002; 59(1): 62-69.
55. Baker RW, Brown E, Akiskal HS, et al. Efficacy of olanzapine combined with valproate or lithium in the treatment of dysphoric mania. Br J Psychiatry. 2004; 185: 472-478. http://bjp. rcpsych.org/content/185/6/472.long. Accessed January 8, 2017.
56. Benazzi F, Berk M, Frye MA, Wang W, Barraco A, Tohen M. Olanzapine/fluoxetine combination for the treatment of mixed depression in bipolar I disorder: a post hoc analysis. J Clin Psychiatry. 2009; 70(10): 1424-1431.
57. Suppes T, Ketter TA, Gwizdowski IS, et al. First controlled treatment trial of bipolar II hypomania with mixed symptoms: quetiapine versus placebo. J Affect Disord. 2013; 150(1): 37-43. Epub ahead of print Mar 19.
58. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebocontrolled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006; 163(2): 247-256. http://ajp.psychiatryonline.org/doi/pdf/10.1176/appi.ajp.163.2.247. Accessed January 8, 2017.
59. Tohen M, Sutton VK, Calabrese JR, Sachs GS, Bowden CL. Maintenance of response following stabilization of mixed index episodes with olanzapine monotherapy in a randomized, doubleblind, placebo-controlled study of bipolar 1 disorder. J Affect Disord. 2009; 116(1-2): 43-50. Epub ahead of print Dec 2, 2008.
60. Bowden CL, Collins MA, McElroy SL, et al. Relationship of mania symptomatology to maintenance treatment response with divalproex, lithium, or placebo. Neuropsychopharmacology. 2005; 30(10): 1932-1939. http://www.nature.com/npp/journal/v30/n10/pdf/1300788a.pdf. Accessed January 8, 2017.
61. Ketter TA, Kalali AH, Weisler RH. A 6-month, multicenter, openlabel evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes. J Clin Psychiatry. 2004; 65(5): 668-673.
62. Carlson BX, Ketter TA, Sun W, et al. Aripiprazole in combination with lamotrigine for the long-Termtreatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, doubleblind study (CN138-392). Bipolar Disord. 2012; 14(1): 41-53.
63. Woo YS, Bahk WM, Jon DI, et al. Risperidone in the treatment of mixed state bipolar patients: results from a 24-week, multicenter, open-label study in Korea. Psychiatry Clin Neurosci. 2010; 64(1): 28-37. Epub ahead of print Nov 4, 2009.